Phase II clinical trial - Sein métastatique RH+
AIPAC
Sein métastatique RH+
Ouvert depuis le: 04.26.2024
Site: Saint-Cloud
Public cible
Adulte
AIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel
Description de l'essai
The proposed Phase IIb clinical study aims to investigate the safety and efficacy of the active immunotherapy IMP321 in combination (adjunctive) with paclitaxel chemotherapy in patients with hormone receptor-positive metastatic breast cancer.
Liens utiles
ETIENNE BRAIN
Investigateur principal